Zymeworks Inc. ZYME
Updated: 16 Jun 2026
No signal published yet
We already track Zymeworks and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Zymeworks Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zymeworks free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 14, 2026, Zymeworks presented positive Phase 1 data for its antibody-drug conjugate ZW191 at the ESMO Gynaecological Cancers Congress, showing a 78.6% objective response rate in FRα-positive ovarian cancer patients. Additionally, the company announced a new $125 million share repurchase program in May 2026.
What Firelda Watch includes for Zymeworks Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Zymeworks Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Zymeworks free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more